

References

1. A K Agarwal, R Garg, A Ritch, and P Sarkar. Postural orthostatic tachycardia syndrome. *Postgrad Med J*. July, 2007; 83(981): 478-480. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2600095/#__sec1title. Accessed on April 10th, 2019.
2. Autonomic Disorders Information for Patients and Families. *Autonomic Disorders Consortium*. <https://www.rarediseasesnetwork.org/cms/autonomic/Learn-More/Disorder-Definitions>. Accessed on April 10th, 2019.
3. Bernadzikowski, T., Boris, J. R. Therapy for fatigue and cognitive dysfunction in postural orthostatic tachycardia syndrome. *Cardiology in the Young*. 2018; 28(12): 1415-1420. doi.org/10.1017/S1047951118001415. Accessed on January 10th, 2019.
4. Dahan S, Tomljenovic L, Shoenfeld Y. Postural Orthostatic Tachycardia Syndrome (POTS) – A novel member of the autoimmune family. *Lupus*. 2016;25(4):339-342. doi:10.1177/0961203316629558. Accessed on April 10th, 2019.
5. Freeman R, Wieling W, Axelrod FB, et al. Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. *Auton Neurosci* 2011;161:46–48. Accessed on April 10th, 2019.
6. Grubb, B., Kosinski, D., Mouhaffel, A. and Pothoulakis, A. The use of Methylphenidate in the treatment of refractory neurocardiogenic syncope. *Pacing and Clinical Electrophysiology*. 2006;19(5):836-840. Accessed on January 10th, 2019.
7. Kanjwal, K., Saeed, B. Karabin, B., Kanjwal, Y., & Grubb, B. P. Use of Methylphenidate in the Treatment of Patients Suffering from Refractory Postural Tachycardia Syndrome. *American Journal of Therapeutics*. 2012; 19(1): 2-6. doi:10.1097/mjt.0b013e3181dd21d2. Accessed on January 10th, 2019.
8. Kpaeyeh, A. G., Mar, P. L., Raj, V., Black, B. K., Arnold, A. C., Biaggioni, I., Raj, S. R. Hemodynamic Profiles and Tolerability of Modafinil in the Treatment of POTS: a randomized placebo-controlled trial. *Journal of Clinical Psychopharmacology*. 2014; 34(6): 738–741. doi.org/10.1097/JCP.0000000000000221. Accessed on January 10th, 2019.
9. Young, J. Use of Lisdexamfetamine dimesylate in treatment of executive functioning deficits and chronic fatigue syndrome: A double blind, placebo-controlled study. *Psychiatry Research*. 2012:1-7. doi.org/10.1016/j.psychres.2012.09.007. Accessed on January 10th, 2019.